The Use of Apremilast in Psoriasis: An Indian Perspective on Real-World Scenarios

Apremilast, an oral phosphodiesterase-4 inhibitor, is approved for use in the management of psoriasis and psoriatic arthritis. Although its efficacy and safety have been well established in clinical studies, in real-world settings, different practice scenarios have been reported. This review paper s...

Descripción completa

Detalles Bibliográficos
Autores principales: Rajagopalan, Murlidhar, Dogra, Sunil, Saraswat, Abir, Varma, Sachin, Banodkar, Pravin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375310/
https://www.ncbi.nlm.nih.gov/pubmed/34430450
http://dx.doi.org/10.2147/PTT.S320810

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375310/
https://www.ncbi.nlm.nih.gov/pubmed/34430450
http://dx.doi.org/10.2147/PTT.S320810

Ejemplares similares